Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.Ask about treatment

Acute lymphoblastic leukemia (ALL): US-approved treatments and how families in the Gulf can access them

Name: Acute lymphoblastic leukemia (ALL) | Reserve Meds
Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Acute lymphoblastic leukemia (ALL): the short answer

The US FDA has approved six medicines covered on this page for acute lymphoblastic leukemia (ALL), each for a specific group of patients: Blincyto, Kymriah, Tecartus, Aucatzyl, Imkeldi and Jylamvo. On 17 October 2026, four of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Blincyto, Kymriah, Tecartus, Aucatzyl, Imkeldi and Jylamvo.
Gulf registers (checked 17 October 2026): see each medicine below.
Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
Price: Quote on request.

What is acute lymphoblastic leukemia (ALL)?

Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow in which the bone marrow makes too many lymphocytes, a type of white blood cell. It usually gets worse quickly if it is not treated. Signs include tiredness, fever and easy bruising or bleeding, and blood and bone marrow tests are used to diagnose it.^[1]

ALL is the most common type of cancer in children. In the United States it accounts for about 25% of all childhood cancers and occurs most often in children aged 1 to 4 years. It also occurs in adults.^[2]

Treatment depends on age, the type of ALL and gene changes in the leukemia cells, such as the Philadelphia chromosome. Some US labels also refer to minimal residual disease (MRD), meaning a small number of leukemia cells that can still be found during remission.^{[1, 2, 3]}

Acute lymphoblastic leukemia (ALL) in the Gulf

Gulf researchers have reviewed childhood leukemia in Saudi Arabia, including epidemiological trends and clinical characteristics, and hematologists in the region have published a consensus on managing delayed methotrexate elimination during high-dose therapy.^{[4, 5]}

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 4 of 6 were listed in Saudi Arabia and 4 of 6 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.^{[6, 7]}

US FDA-approved medicines for acute lymphoblastic leukemia (ALL)

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Blincyto (blinatumomab)
US FDA-approved for adults and children one month and older with CD19-positive B-cell precursor ALL: in remission but with minimal residual disease of 0.1% or more, after relapse or when the disease does not respond, and in the consolidation phase for Philadelphia chromosome-negative disease. It is given by intravenous infusion.^[3]
Current US label version: 14 April 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, India
Kymriah (tisagenlecleucel)
US FDA-approved for patients up to 25 years old with B-cell precursor ALL that has not responded to treatment or has come back a second time or more. It is a CAR-T cell therapy made from the patient's own T cells and given once.^[8]
Current US label version: 16 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, Egypt
Tecartus (brexucabtagene autoleucel)
US FDA-approved for adults with B-cell precursor ALL that has come back or has not responded to treatment. It is a CAR-T cell therapy made from the patient's own T cells.^[9]
Current US label version: 16 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Aucatzyl (obecabtagene autoleucel)
US FDA-approved for adults with B-cell precursor ALL that has come back or has not responded to treatment. It is a CAR-T cell therapy made from the patient's own T cells.^[10]
Current US label version: 23 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, Kuwait, Jordan, India
Imkeldi (imatinib oral solution)
US FDA-approved for Philadelphia chromosome-positive ALL: adults whose disease has come back or not responded, and children with newly diagnosed disease together with chemotherapy. It is an oral solution of imatinib.^[11]
Current US label version: 5 December 2024. Gulf registers: Saudi Arabia (SFDA drugs list): not found under this brand; products with the same active ingredient are listed (for example Cemivil, Glivec, Imalar). Abu Dhabi (DoH drug code list): not found under this brand; products with the same active ingredient are listed (for example Adalbern, Cemivil, Glivec). Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, Kuwait, Egypt, Lebanon, Turkey
Jylamvo (methotrexate oral solution)
US FDA-approved for adults and children with ALL as part of a combination chemotherapy maintenance regimen. It is an oral solution of methotrexate.^[12]
Current US label version: 8 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[6, 7]}
Country access guides: Saudi Arabia, UAE, Bahrain, Egypt, Turkey, Pakistan

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.^{[13, 14]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

For Kymriah, Tecartus and Aucatzyl. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment, which may be abroad. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for acute lymphoblastic leukemia (ALL)

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for acute lymphoblastic leukemia (ALL)?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Blincyto, Kymriah, Tecartus, Aucatzyl, Imkeldi and Jylamvo. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Blincyto available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Blincyto?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

What is MRD-positive ALL?

It means a small number of leukemia cells can still be found after treatment, even though the patient is in remission. Blincyto's US label covers CD19-positive B-cell precursor ALL in remission with MRD of 0.1% or more.

Sources for the condition-specific answers: ^[3]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.